De-Escalation of neoadjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Docetaxel (Primary) ; Paclitaxel (Primary) ; Pertuzumab/trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms DECRESCENDO
- 08 Mar 2024 This trial has been Discontinued in Italy, according to European Clinical Trials Database record.
- 16 Nov 2023 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 24 Jul 2023 This trial has been suspended in Ireland, according to European Clinical Trials Database record.